World News

Measles cases have increased globally, with an estimated 11 million infections in 2024—about 800,000 more than pre-pandemic levels in 2019.

Mjn-neuro’s wearable sensor uses artificial intelligence (AI) to analyze electrical brain signals and predict when a seizure will occur.

WT-7695, a preclinical radiopharmaceutical targeting carbonic anhydrase IX (CA9), was developed in collaboration with the University of Wisconsin-Madison, and SK now holds exclusive worldwide rights to develop, manufacture, and market the drug.

The partnership combines Philips’ next-generation MR technology with Cortechs.ai’s AI-driven quantitative neuroimaging software to transform how doctors detect, monitor, and manage neurological diseases.

The acquisition centers on Alcyone’s innovative ThecaFlex DRx drug delivery system, an experimental implantable device that represents a significant advancement in treating neurological disorders.

Construction at the MTC is currently underway and is scheduled for completion during the first half of 2027.

GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.

The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).

The acquisition aims to connect ambulatory care centers, teleradiology services, and hospital systems through unified imaging technology.

A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.